Dominic Theuns, Fehra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4866427/publications.pdf

Version: 2024-02-01

98 papers

4,711 citations

147566 31 h-index 98622 67 g-index

98 all docs 98 docs citations 98 times ranked

3323 citing authors

#	Article	IF	CITATIONS
1	EHRA certification: a 15-year journey of attesting excellence in arrhythmia healthcare. Europace, 2022, 24, 175-178.	0.7	1
2	Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study. European Heart Journal, 2022, 43, 2037-2050.	1.0	47
3	Pocket hematoma after pacemaker or defibrillator surgery: Direct oral anticoagulants versus vitamin K antagonists. IJC Heart and Vasculature, 2022, 39, 101005.	0.6	1
4	Accuracy of atrial fibrillation detection by an insertable cardiac monitor in patients undergoing catheter ablation: Results of the <scp>BioVAD</scp> study. Annals of Noninvasive Electrocardiology, 2022, 27, e12960.	0.5	4
5	Efficacy and safety of transvenous lead extraction using a liberal combined superior and femoral approach. Journal of Interventional Cardiac Electrophysiology, 2021, 62, 239-248.	0.6	6
6	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation, 2021, 143, 7-17.	1.6	132
7	Incremental Value of an Insertable Cardiac Monitor in Patients with Hypertrophic Cardiomyopathy with Low or Intermediate Risk for Sudden Cardiac Death. Cardiology, 2021, 146, 207-212.	0.6	7
8	Comprehensive multicomponent cardiac rehabilitation in cardiac implantable electronic devices recipients: a consensus document from the European Association of Preventive Cardiology (EAPC;) Tj ETQq0 0 0	rgBT/Ove	erlogk 10 Tf 50
	European Journal of Preventive Cardiology, 2021, 28, 1736-1752. Comprehensive multicomponent cardiac rehabilitation in cardiac implantable electronic devices		
9	recipients: a consensus document from the European Association of Preventive Cardiology (EAPC;) Tj ETQq1 1 0 Europace, 2021, 23, 1336-1337o.	.784314 r 0.7	gBŢ /Overlock
10	Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. Europace, 2021, 23, 887-897.	0.7	19
11	Dutch Outcome in Implantable Cardioverterâ€Defibrillator Therapy: Implantable Cardioverterâ€Defibrillator–Related Complications in a Contemporary Primary Prevention Cohort. Journal of the American Heart Association, 2021, 10, e018063.	1.6	8
12	Clinical Update of the Latest Evidence for CardioMEMS Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Promising System for Remote Heart Failure Care. Sensors, 2021, 21, 2335.	2.1	13
13	Reassessment of clinical variables in cardiac resynchronization defibrillator patients at the time of first replacement:ÂDeath after replacement of CRT (DARC) score. Journal of Cardiovascular Electrophysiology, 2021, 32, 1687-1694.	0.8	2
14	Remote Monitoring of Heart Failure in Patients with Implantable Cardioverter-Defibrillators: Current Status and Future Needs. Sensors, 2021, 21, 3763.	2.1	10
15	Application of the heart failure meta-score to predict prognosis in patients with cardiac resynchronization defibrillators. International Journal of Cardiology, 2021, 330, 73-79.	0.8	5
16	Sexâ€specific differences in outcome and risk stratification of ventricular arrhythmias in implantable cardioverter defibrillator patients. ESC Heart Failure, 2021, 8, 3726-3736.	1.4	4
17	Implantable loop recorders in patients with heart disease: comparison between patients with and without syncope. Open Heart, 2021, 8, e001748.	0.9	2
18	The value of remote care in the reduction of healthcare utilization in implantable cardioverterâ€defibrillator patients. PACE - Pacing and Clinical Electrophysiology, 2021, , .	0.5	2

#	Article	IF	Citations
19	Anger and mortality following ICD implantation: Authors' reply. Europace, 2021, 23, 650-650.	0.7	1
20	Anxiety, depression, ventricular arrhythmias and mortality in patients with an implantable cardioverter defibrillator: 7Âyears' follow-up of the MIDAS cohort. General Hospital Psychiatry, 2020, 66, 154-160.	1.2	11
21	Anger and long-term mortality and ventricular arrhythmias in patients with a first-time implantable cardioverter-defibrillator: data from the MIDAS study. Europace, 2020, 22, 1054-1061.	0.7	3
22	Early detection of ventricular arrhythmias in adults with congenital heart disease using an insertable cardiac monitor (EDVA-CHD study). International Journal of Cardiology, 2020, 305, 63-69.	0.8	13
23	Outcome of Insertable Cardiac Monitors in Symptomatic Patients with Brugada Syndrome at Low Risk of Sudden Cardiac Death. Cardiology, 2020, 145, 413-420.	0.6	11
24	Evaluation of subcutaneous implantable cardioverter-defibrillator performance in patients with ion channelopathies from the EFFORTLESS cohort and comparison with a meta-analysis of transvenous ICD outcomes. Heart Rhythm O2, 2020, 1 , $326-335$.	0.6	26
25	Emerging electromagnetic interferences between implantable cardioverter-defibrillators and left ventricular assist devices. Europace, 2020, 22, 584-587.	0.7	22
26	Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study. Cardiology Journal, 2020, 26, 711-716.	0.5	1
27	Emerging electromagnetic interferences between implantable cardioverter-defibrillators and left ventricular assist devices: Authors' reply. Europace, 2020, 22, 1911-1912.	0.7	1
28	High Cerebrovascular Thromboembolic Event Rate Long after Unsuccessful Catheter Ablation for Atrial Fibrillation. Journal of Atrial Fibrillation, 2020, 13, 2294.	0.5	1
29	Quality of life, depression, and anxiety in patients with a subcutaneous versus transvenous defibrillator system. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1541-1551.	0.5	11
30	Predicting Early Mortality Among Implantable Defibrillator Patients Treated With Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2019, 25, 812-818.	0.7	2
31	Evaluation of recurrent ventricular tachyarrhythmias in patients who survived out-of-hospital cardiac arrest due to ventricular fibrillation: eligibility for subcutaneous implantable defibrillator therapy. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 317-323.	0.6	4
32	Predicting defibrillator benefit in patients with cardiac resynchronization therapy: A competing risk study. Heart Rhythm, 2019, 16, 1057-1064.	0.3	7
33	Usefulness of a standard 12-lead electrocardiogram to predict the eligibility for a subcutaneous defibrillator. Journal of Electrocardiology, 2019, 55, 123-127.	0.4	3
34	Insertable cardiac monitors: current indications and devices. Expert Review of Medical Devices, 2019, 16, 45-55.	1.4	30
35	Atrial fibrillation reduction by renal sympathetic denervation: 12 months' results of the AFFORD study. Clinical Research in Cardiology, 2019, 108, 634-642.	1.5	38
36	Conduction dynamics after transcatheter aortic valve implantation and implications for permanent pacemaker implantation and early discharge: the CONDUCT-study. Europace, 2018, 20, 1981-1988.	0.7	11

#	Article	IF	CITATIONS
37	Sixâ€year followâ€up of the initial Dutch subcutaneous implantable cardioverterâ€defibrillator cohort: Longâ€term complications, replacements, and battery longevity. Journal of Cardiovascular Electrophysiology, 2018, 29, 1010-1016.	0.8	39
38	Value of implantable loop recorders in patients with structural or electrical heart disease. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 203-208.	0.6	15
39	Procedural and long-term outcome after catheter ablation of idiopathic outflow tract ventricular arrhythmias: comparing manual, contact force, and magnetic navigated ablation. Europace, 2018, 20, ii22-ii27.	0.7	9
40	Increased risk of ventricular arrhythmias in survivors of out-of-hospital cardiac arrest with chronic total coronary occlusion. Heart Rhythm, 2018, 15, 124-129.	0.3	22
41	Frequency of Need for Antitachycardia or Antibradycardia Pacing or Cardiac Resynchronization Therapy in Patients With a Single-Chamber Implantable Cardioverter-Defibrillator. American Journal of Cardiology, 2018, 122, 2068-2074.	0.7	4
42	Evaluation of a novel automatic screening tool for determining eligibility for a subcutaneous implantable cardioverter-defibrillator. International Journal of Cardiology, 2018, 272, 97-101.	0.8	15
43	Psychological distress in patients with an implantable cardioverter defibrillator and their partners. Journal of Psychosomatic Research, 2018, 113, 16-21.	1.2	15
44	Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm, 2018, 15, 1515-1522.	0.3	123
45	Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm, 2017, 14, 367-375.	0.3	30
46	Comparison of Multivariate Risk Estimation Models to Predict Prognosis in Patients With Implantable Cardioverter Defibrillators With or Without Cardiac Resynchronization Therapy. American Journal of Cardiology, 2017, 119, 1414-1420.	0.7	6
47	Questioning the preference for dual- vs. single-chamber implantable defibrillator in primary prevention implantable cardioverter-defibrillator recipients. Europace, 2017, 19, 1416-1417.	0.7	1
48	Type and rate of atrial fibrillation termination due to rotational activity ablation combined with pulmonary vein isolation. Journal of Cardiovascular Electrophysiology, 2017, 28, 862-869.	0.8	12
49	Nationwide Longitudinal Follow-Up ofÂRiata Leads Under Advisory at 3ÂAnnualÂScreenings. JACC: Clinical Electrophysiology, 2017, 3, 887-893.	1.3	4
50	Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry. Journal of the American College of Cardiology, 2017, 70, 830-841.	1.2	266
51	Remote monitoring of heart failure: benefits for therapeutic decision making. Expert Review of Cardiovascular Therapy, 2017, 15, 503-515.	0.6	23
52	Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 119, 100-105.	0.7	40
53	Web-based distress management for implantable cardioverter defibrillator patients: A randomized controlled trial Health Psychology, 2017, 36, 392-401.	1.3	21

A Comparison of the Quality of Life of Patients With an Entirely Subcutaneous Implantable
Defibrillator System Versus a Transvenous System (from the EFFORTLESS S-ICD Quality of Life) Tj ETQq0 0 0 rgBT /Oværlock 127 Tf 50 57

#	Article	IF	CITATIONS
55	Comparative study of the failure rates among 3 implantable defibrillator leads. Heart Rhythm, 2016, 13, 2299-2305.	0.3	16
56	Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm, 2016, 13, 1066-1074.	0.3	92
57	Non-sustained ventricular tachycardia in patients with congenital heart disease: An important sign?. International Journal of Cardiology, 2016, 206, 158-163.	0.8	15
58	Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. Heart Rhythm, 2016, 13, 157-164.	0.3	67
59	The learning curve associated with the introduction of the subcutaneous implantable defibrillator. Europace, 2016, 18, 1010-1015.	0.7	95
60	Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time. Europace, 2016, 18, 710-717.	0.7	41
61	Air entrapment causing early inappropriate shocks in a patient with a subcutaneous cardioverter-defibrillator. HeartRhythm Case Reports, 2015, 1, 156-158.	0.2	14
62	The Effect of Elapsed Time from Myocardial Infarction on Mortality and Major Adverse Cardiac and Cerebrovascular Events in ICD Patients. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1448-1455.	0.5	1
63	Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management. International Journal of Cardiology, 2015, 195, 126-133.	0.8	120
64	Validation of the 2014 European Society of Cardiology Guidelines Risk Prediction Model for the Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 829-835.	2.1	113
65	Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. Journal of the American College of Cardiology, 2015, 65, 1605-1615.	1.2	458
66	Trajectories of Patient-Reported Health Status in Patients With an Implantable Cardioverter Defibrillator. American Journal of Cardiology, 2015, 115, 771-777.	0.7	11
67	Patients with congenital heart disease: how to determine the eligibility for implantation of a subcutaneous implantable defibrillator?. Europace, 2015, 17, 1003-1004.	0.7	O
68	Longevity of the Subcutaneous Implantable Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1159-1163.	2.1	37
69	A prospective study on safety of catheter ablation procedures: Contact force guided ablation could reduce the risk of cardiac perforation. International Journal of Cardiology, 2015, 179, 441-448.	0.8	44
70	Ventricular Tachyarrhythmias and Mortality in Patients With an Implantable Cardioverter Defibrillator. Psychosomatic Medicine, 2014, 76, 58-65.	1.3	38
71	Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. European Heart Journal, 2014, 35, 1657-1665.	1.0	410
72	Information provision, satisfaction and emotional distress in patients with an implantable cardioverter-defibrillator. International Journal of Cardiology, 2014, 177, 586-588.	0.8	11

#	Article	IF	Citations
73	Long-term mortality risk in patients with an implantable cardioverter–defibrillator: Influence of heart rate and QRS duration. International Journal of Cardiology, 2014, 175, 560-564.	0.8	6
74	Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. Heart, 2014, 100, 1188-1192.	1.2	31
75	Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm, 2014, 11, 1352-1358.	0.3	86
76	Poor health status and distress in cardiac patients: the role of device therapy vs. underlying heart disease. Europace, 2013, 15, 355-361.	0.7	20
77	Comorbidity burden is associated with poor psychological well-being and physical health status in patients with an implantable cardioverter-defibrillator. Europace, 2013, 15, 1468-1474.	0.7	31
78	Shock and Patient Preimplantation Type D Personality Are Associated With Poor Health Status in Patients With Implantable Cardioverter-Defibrillator. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 373-380.	0.9	25
79	Prevalence and Presentation of Externalized Conductors and Electrical Abnormalities in Riata Defibrillator Leads After Fluoroscopic Screening. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 1059-1063.	2.1	49
80	The Entirely Subcutaneous Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2012, 60, 1933-1939.	1.2	205
81	Prognostic Role of Highâ€Sensitivity Câ€Reactive Protein and Bâ€Type Natriuretic Peptide in Implantable Cardioverterâ€Defibrillator Patients. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 275-282.	0.5	10
82	Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the Sâ€ICD: Design and Rationale of the EFFORTLESS Sâ€ICD Registry. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 574-579.	0.5	42
83	Risk of chronic anxiety in implantable defibrillator patients: A multi-center study. International Journal of Cardiology, 2011, 147, 420-423.	0.8	59
84	The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace, 2011, 13, 62-69.	0.7	77
85	Course of anxiety and device-related concerns in implantable cardioverter defibrillator patients the first year post implantation. Europace, 2010, 12, 1119-1126.	0.7	57
86	Close connection between improvement in left ventricular function by cardiac resynchronization therapy and the incidence of arrhythmias in cardiac resynchronization therapyâ€defibrillator patients. European Journal of Heart Failure, 2010, 12, 1325-1332.	2.9	35
87	An Entirely Subcutaneous Implantable Cardioverter–Defibrillator. New England Journal of Medicine, 2010, 363, 36-44.	13.9	686
88	Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace, 2010, 12, 1564-1570.	0.7	142
89	Defibrillation threshold testing at implantation: can we predict the patient with a high defibrillation threshold?. Europace, 2010, 12, 309-310.	0.7	4
90	Analysis of 57,148 Transmissions by Remote Monitoring of Implantable Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S63-S65.	0.5	32

#	Article	IF	CITATIONS
91	Prevention of inappropriate therapy in implantable defibrillators: A meta-analysis of clinical trials comparing single-chamber and dual-chamber arrhythmia discrimination algorithms. International Journal of Cardiology, 2008, 125, 352-357.	0.8	77
92	Morphology discrimination in implantable cardioverter-defibrillators: consistency of template match percentage during atrial tachyarrhythmias at different heart rates. Europace, 2008, 10, 1060-1066.	0.7	25
93	Evaluation of morphology discrimination for ventricular tachycardia diagnosis in implantable cardioverter-defibrillators. Heart Rhythm, 2006, 3, 1332-1338.	0.3	26
94	Clinical variables predicting inappropriate use of implantable cardioverter-defibrillator in patients with coronary heart disease or nonischemic dilated cardiomyopathy. American Journal of Cardiology, 2005, 95, 271-274.	0.7	43
95	Outcome in patients with an ICD incorporating cardiac resynchronisation therapy: Differences between primary and secondary prophylaxis. European Journal of Heart Failure, 2005, 7, 1027-1032.	2.9	13
96	Defibrillation efficacy testing: Long-term follow-up and mortality. Europace, 2005, 7, 509-515.	0.7	26
97	Ice mapping during cryothermal ablation of accessory pathways in WPW: the role of the temperature time constant. Europace, 2004, 6, 116-122.	0.7	32
98	Prevention of inappropriate therapy in implantable cardioverter-defibrillators. Journal of the American College of Cardiology, 2004, 44, 2362-2367.	1.2	145